SAREPTA THERAPEUTICS, INC. Current Liabilities
SAREPTA THERAPEUTICS, INC. (SRPT) had Current Liabilities of $502.91 million as of 2026-06-30, per its 10-Q filed 2026-08-05.
Financial Statements › Balance Sheet › Liabilities › Liabilities, Current
us-gaap:LiabilitiesCurrent · last filed 2026-08-05
- 2026-06-30: Liabilities, Current $502.91M.
- 2026-03-31: Liabilities, Current $499.16M.
- 2025-12-31: Liabilities, Current $1.10B.
- 2025-09-30: Liabilities, Current $921.42M.
| Period end | Liabilities, Current |
|---|---|
| 2026-06-30 | $502.91M 10-Q · filed 2026-08-05 |
| 2026-03-31 | $499.16M 10-Q · filed 2026-05-06 |
| 2025-12-31 | $1.10B 10-Q · filed 2026-08-05 |
| 2025-09-30 | $921.42M 10-Q · filed 2025-11-06 |
| 2025-06-30 | $919.95M 10-Q · filed 2025-08-06 |
| 2025-03-31 | $605.59M 10-Q · filed 2025-05-06 |
| 2024-12-31 | $731.68M 10-K · filed 2026-03-02 |
| 2024-09-30 | $699.49M 10-Q · filed 2024-11-06 |
| 2024-06-30 | $688.49M 10-Q · filed 2024-08-07 |
| 2024-03-31 | $608.71M 10-Q · filed 2024-05-01 |
| 2023-12-31 | $653.66M 10-K · filed 2025-02-28 |
| 2023-09-30 | $450.74M 10-Q · filed 2023-11-01 |
| 2023-06-30 | $498.65M 10-Q · filed 2023-08-02 |
| 2023-03-31 | $536.88M 10-Q · filed 2023-05-02 |
| 2022-12-31 | $619.60M 10-K · filed 2024-02-28 |
| 2022-09-30 | $602.92M 10-Q · filed 2022-11-02 |
| 2022-06-30 | $545.57M 10-Q · filed 2022-08-02 |
| 2022-03-31 | $454.96M 10-Q · filed 2022-05-04 |
| 2021-12-31 | $452.73M 10-K · filed 2023-02-28 |
| 2021-09-30 | $373.44M 10-Q · filed 2021-11-03 |
| 2021-06-30 | $425.02M 10-Q · filed 2021-08-04 |
| 2021-03-31 | $364.74M 10-Q · filed 2021-05-05 |
| 2020-12-31 | $416.03M 10-K · filed 2022-03-01 |
| 2020-09-30 | $378.39M 10-Q · filed 2020-11-05 |
| 2020-06-30 | $354.90M 10-Q · filed 2020-08-05 |
| 2020-03-31 | $306.43M 10-Q · filed 2020-05-06 |
| 2019-12-31 | $264.77M 10-K · filed 2021-03-01 |
| 2019-09-30 | $215.86M 10-Q · filed 2019-11-07 |
| 2019-06-30 | $162.09M 10-Q · filed 2019-08-07 |
| 2019-03-31 | $137.37M 10-Q · filed 2019-05-08 |
| 2018-12-31 | $173.69M 10-K · filed 2020-02-26 |
| 2018-09-30 | $114.39M 10-Q · filed 2018-10-31 |
| 2018-06-30 | $104.69M 10-Q · filed 2018-08-08 |
| 2018-03-31 | $91.20M 10-Q · filed 2018-05-03 |
| 2017-12-31 | $88.33M 10-K · filed 2019-02-28 |
| 2017-09-30 | $70.47M 10-Q · filed 2017-11-01 |
| 2017-06-30 | $65.96M 10-Q · filed 2017-08-03 |
| 2017-03-31 | $74.63M 10-Q · filed 2017-05-04 |
| 2016-12-31 | $75.42M 10-K · filed 2018-03-01 |
| 2016-09-30 | $64.93M 10-Q · filed 2016-11-07 |
| 2016-06-30 | $66.93M 10-Q · filed 2016-08-09 |
| 2016-03-31 | $55.16M 10-Q · filed 2016-05-05 |
| 2015-12-31 | $62.29M 10-K · filed 2017-02-28 |
| 2015-09-30 | $37.67M 10-Q · filed 2015-11-05 |
| 2015-06-30 | $38.96M 10-Q · filed 2015-08-06 |
| 2015-03-31 | $33.91M 10-Q · filed 2015-05-07 |
| 2014-12-31 | $36.87M 10-K · filed 2016-02-25 |
| 2014-09-30 | $22.73M 10-Q · filed 2014-11-06 |
| 2014-06-30 | $29.40M 10-Q · filed 2014-08-07 |
| 2014-03-31 | $37.76M 10-Q · filed 2014-05-08 |
| 2013-12-31 | $35.97M 10-K · filed 2015-02-26 |
| 2013-09-30 | $51.10M 10-Q · filed 2013-11-12 |
| 2013-06-30 | $92.43M 10-Q · filed 2013-08-08 |
| 2013-03-31 | $103.66M 10-Q · filed 2013-05-09 |
| 2012-12-31 | $78.89M 10-K · filed 2014-03-03 |
| 2012-09-30 | $55.20M 10-Q · filed 2012-11-07 |
| 2012-06-30 | $17.13M 10-Q · filed 2012-08-07 |
| 2012-03-31 | $29.92M 10-Q · filed 2012-05-10 |
| 2011-12-31 | $20.60M 10-K · filed 2013-03-15 |
| 2011-09-30 | $26.53M 10-Q · filed 2011-11-08 |
| 2011-06-30 | $36.94M 10-Q · filed 2011-08-08 |
| 2010-12-31 | $45.86M 10-K · filed 2012-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AGIOS PHARMACEUTICALS, INC. (AGIO) | United States | $1.962B | -5.38 |
| Zymeworks Inc. (ZYME) | United States | $1.902B | -12.44 |
| Biohaven Ltd. (BHVN) | United States | $1.990B | -3.83 |
| Nuvation Bio Inc. (NUVB) | United States | $2.007B | -13.12 |
| UroGen Pharma Ltd. (URGN) | $2.015B | -18.42 | |
| NEKTAR THERAPEUTICS (NKTR) | United States | $2.026B | -9.05 |
| PERRIGO Co plc (PRGO) | Ireland | $2.038B | -0.79 |
| Generate Biomedicines, Inc. (GENB) | United States | $2.052B | |
| COMPASS Pathways plc (CMPS) | $1.812B | -4.87 | |
| ANI PHARMACEUTICALS INC (ANIP) | United States | $1.810B | 18.77 |